Skip to content

Organon OGN Payments to Acquire Intangible Assets

Payments to Acquire Intangible Assets at other companies

Biogen logo
BiogenBIIB
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
HRO
HarrowHROW
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%
Debt / equity9.5×-7.0×
Current ratio+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireIntangibleAssets.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's payments to acquire intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's payments to acquire intangible assets?
Organon (OGN) reported payments to acquire intangible assets of $0 in Q1 2026.
How has Organon's payments to acquire intangible assets changed year-over-year?
Organon's payments to acquire intangible assets decreased by 100.0% year-over-year, from $55M to $0.
What is the long-term trend for Organon's payments to acquire intangible assets?
Over 2 years (2022 to 2024), Organon's payments to acquire intangible assets has grown at a -8.0% compound annual growth rate (CAGR), from $124M to $105M.